TriSalus Life Sciences, Inc.
TLSI
$5.49
$0.244.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.14M | 29.43M | 26.89M | 24.74M | 21.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.14M | 29.43M | 26.89M | 24.74M | 21.98M |
| Cost of Revenue | 4.63M | 4.10M | 3.47M | 3.05M | 2.91M |
| Gross Profit | 27.51M | 25.33M | 23.42M | 21.68M | 19.07M |
| SG&A Expenses | 44.20M | 43.81M | 42.04M | 42.31M | 40.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.96M | 65.60M | 68.01M | 73.15M | 73.65M |
| Operating Income | -31.82M | -36.17M | -41.12M | -48.41M | -51.67M |
| Income Before Tax | -27.21M | -30.04M | -55.57M | -54.59M | -64.23M |
| Income Tax Expenses | 8.00K | 6.00K | 8.00K | 11.00K | 17.00K |
| Earnings from Continuing Operations | -27.21 | -30.05 | -55.58 | -54.60 | -64.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.21M | -30.05M | -55.58M | -54.60M | -64.24M |
| EBIT | -31.82M | -36.17M | -41.12M | -48.41M | -51.67M |
| EBITDA | -31.09M | -35.43M | -40.39M | -47.69M | -51.00M |
| EPS Basic | -1.12 | -1.33 | -2.50 | -2.53 | -38.15 |
| Normalized Basic EPS | -1.00 | -1.04 | -1.49 | -2.23 | -22.18 |
| EPS Diluted | -1.12 | -1.33 | -2.50 | -2.53 | -38.15 |
| Normalized Diluted EPS | -1.00 | -1.04 | -1.49 | -2.23 | -22.18 |
| Average Basic Shares Outstanding | 106.48M | 101.28M | 96.96M | 83.63M | 60.17M |
| Average Diluted Shares Outstanding | 106.48M | 101.28M | 96.96M | 83.63M | 60.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |